Abstract
Arrow’s (1963) seminal work on ‘Uncertainty and the economics of medical care’ laid the foundation of welfare economics analysis of health programs. An important area of health economics is the application of cost benefit analysis and its associated methodologies in project planning and economic evaluation of health policies and health programs. Economic evaluation in the area of reimbursement of pharmaceuticals attracts most attention. Cost benefit analysis estimates net social welfare changes as a result of a program or a policy, with social welfare being measured in terms of net benefits of the program. A body of literature exists in this area following Arrow’s (1963) seminal work (Drummond et al. 1997; Williams 1997; Carter and Harris 1999; jack 1999; Johannesson 2000; Carter 2001; Islam 2001; Brent 2003). However, there are significant limitations in the current literature. In order to improve its effectiveness and usefulness, economic evaluation of health programs requires adjustment based on normative social choice theory.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
